N Engl J Med:4个月的莫西沙星方案治疗结核病效果欠佳

2015-02-04 高晓方 编译 医学论坛网

在一项随机对照试验中,两种4个月疗程的莫西沙星方案均劣于标准的6个月疗程方案。 结核患者需接受6个月疗程的药物治疗引发了依从性、不良反应和治疗费用等诸多问题。莫西沙星具有抗分枝杆菌活性的发现,为应用该药物缩短结核病治疗疗程提供了可能。 在近期一项跨国的、随机、安慰剂对照、非劣性试验中,1931例新近诊断、既往未治疗且药物敏感的成人结核患者被纳入研究;研究者对比了标准的6个月方案

在一项随机对照试验中,两种4个月疗程的莫西沙星方案均劣于标准的6个月疗程方案。

结核患者需接受6个月疗程的药物治疗引发了依从性、不良反应和治疗费用等诸多问题。莫西沙星具有抗分枝杆菌活性的发现,为应用该药物缩短结核病治疗疗程提供了可能。

在近期一项跨国的、随机、安慰剂对照、非劣性试验中,1931例新近诊断、既往未治疗且药物敏感的成人结核患者被纳入研究;研究者对比了标准的6个月方案(8周乙胺丁醇/异烟肼/利福平/吡嗪酰胺,继之以18周异烟肼/利福平)和两种4个月的含莫西沙星的方案:一种含异烟肼(8周莫西沙星/异烟肼/利福平/吡嗪酰胺,继之以9周莫西沙星/异烟肼/利福平和9周安慰剂);另一种含乙胺丁醇,8周莫西沙星/乙胺丁醇/利福平/吡嗪酰胺,继之以9周莫西沙星/利福平和9周安慰剂)。预定义非劣性为治疗结束后18个月内良好治疗转归的组间差异<6%。

莫西沙星方案转化到培养阴性状态的速度快于标准治疗方案。然而,遵循研究设计分析显示两种莫西沙星方案均劣于标准方案:含异烟肼的莫西沙星方案良好转归率为85%,含乙胺丁醇的莫西沙星方案为80%,标准方案则为92%。不良转归的最常见原因为转化到培养阴性状态后复发。在改良意向治疗分析中得出了与之相似的结果。

评论

尽管可以设想对其他4个月疗程的莫西沙星方案进行研究,但当前结果不鼓励这样的试验。该试验的一项关键结果为,在莫西沙星方案中见到的更短培养转化时间并不能准确预测远期转归。未来需要对此现象的发生原因进行更深入的了解。

原始出处:

Four-Month Moxifloxacin Regimens Less Effective for TB Treatment Richard T.Ellison III, MD reviewing Gillespie SH et al. N Engl J Med 2014 Sep 7. 


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2081329, encodeId=2f46208132943, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Dec 13 09:15:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785437, encodeId=d3651e854375a, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed May 06 22:15:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15946, encodeId=b21d15946f5, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:54:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253947, encodeId=5c1c125394e11, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri Feb 06 04:15:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606395, encodeId=870e1606395b6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 06 04:15:00 CST 2015, time=2015-02-06, status=1, ipAttribution=)]
    2015-12-13 spoonycyy
  2. [GetPortalCommentsPageByObjectIdResponse(id=2081329, encodeId=2f46208132943, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Dec 13 09:15:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785437, encodeId=d3651e854375a, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed May 06 22:15:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15946, encodeId=b21d15946f5, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:54:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253947, encodeId=5c1c125394e11, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri Feb 06 04:15:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606395, encodeId=870e1606395b6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 06 04:15:00 CST 2015, time=2015-02-06, status=1, ipAttribution=)]
    2015-05-06 haouestc
  3. [GetPortalCommentsPageByObjectIdResponse(id=2081329, encodeId=2f46208132943, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Dec 13 09:15:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785437, encodeId=d3651e854375a, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed May 06 22:15:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15946, encodeId=b21d15946f5, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:54:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253947, encodeId=5c1c125394e11, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri Feb 06 04:15:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606395, encodeId=870e1606395b6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 06 04:15:00 CST 2015, time=2015-02-06, status=1, ipAttribution=)]
    2015-02-16 windmilL1989

    已阅

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2081329, encodeId=2f46208132943, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Dec 13 09:15:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785437, encodeId=d3651e854375a, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed May 06 22:15:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15946, encodeId=b21d15946f5, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:54:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253947, encodeId=5c1c125394e11, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri Feb 06 04:15:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606395, encodeId=870e1606395b6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 06 04:15:00 CST 2015, time=2015-02-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2081329, encodeId=2f46208132943, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Dec 13 09:15:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785437, encodeId=d3651e854375a, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Wed May 06 22:15:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15946, encodeId=b21d15946f5, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:54:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253947, encodeId=5c1c125394e11, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri Feb 06 04:15:00 CST 2015, time=2015-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606395, encodeId=870e1606395b6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Feb 06 04:15:00 CST 2015, time=2015-02-06, status=1, ipAttribution=)]

相关资讯

Clin Infect Dis:莫西沙星10 mg/kg/d方案对于儿童患者而言是否足够

目前有学者推荐使用莫西沙星 7.5-10 mg/kg方案治疗多重耐药性TB感染患儿。研究已报道,成人患者口服400 mg莫西沙星后AUC为40-60µg•h/ml,但莫西沙星应用于结核患儿的药代动力学和长期安全性数据仍不足。方法:在一项前瞻性药代动力学及安全性研究中,南非开普敦市的7-15岁儿童常规接受莫西沙星 10 mg/kg/d,作为多重耐药性结核(MDR-TB)多药联合治疗的一部分。莫西沙星

NEJM:短疗程莫西沙星疗法能否治疗药物敏感型结核?

研究背景: 前期及临床前试验的研究结果提示使用包含莫西沙星的治疗方案四个月能有效治疗单纯痰涂片阳性的肺结核。 研究方法: 我们开展了一项随机、双盲、安慰剂对照的3期临床试验对两种包含莫西沙星的治疗方案与一组对照组进行非劣效性的比较。一组患者接受为期8周的异烟肼、利福平、吡嗪酰胺和乙胺丁醇,异烟肼和利福平后继使用18周,此组作为对照组;在第二组中,我们用莫西沙星代替乙胺丁醇治疗17

CMAJ:抗生素莫西沙星和左氧氟沙星或引发老年人肝脏损伤风险

近日,来自加拿大的研究人员表示,抗生素莫西沙星(moxifloxacin)和左氧氟沙星(levofloxacin)应当进行有效地监管控制,因为服用这两种抗生素对老年人有潜在的肝损伤风险。 相比使用抗生素克拉霉素,这些抗生素带来的肝损伤风险是前者的两倍。肝脏损伤包括中毒性肝病、肝炎、肝坏死或者未指明的急性肝衰竭。 “氟喹诺酮类抗生素是北美使用最广泛的一类抗生素,广谱福喹诺酮类抗生素的使用如左氧氟

4个月的莫西沙星方案在结核治疗方面效果欠佳

在一项随机对照试验中,两种4个月疗程的莫西沙星方案均劣于标准的6个月疗程方案。 结核患者需接受为期6个月的药物治疗引发了依从性、不良反应和治疗费用等诸多问题。莫西沙星具有抗分枝杆菌活性的发现,为应用该药物缩短治疗疗程提供了可能。 在近期一项跨国、随机、安慰剂对照、非劣性试验中,1931例新近诊断、既往未治疗且药物敏感的成人结核患者被纳入研究;研究者对比了标准的6个月方案(8周乙胺丁醇/异烟肼/

NEJM: 高剂量的利福喷汀联合莫西沙星治疗肺结核

背景:目前治疗肺结核的治疗方案时间太长太复杂,需要新的治疗方案。方法:研究对象为初诊病人、涂片阳性和药物敏感的肺结核患者,随机分为3组。对照组的治疗方案为每天服用乙胺丁醇片、异烟肼、利福平和吡嗪酰胺2个月,接着每天服用异烟肼和利福平4个月;新的治疗方案为每天服用乙胺丁醇片、莫西沙星、利福平和吡嗪酰胺2个月,接着每周两次服用莫西沙星和900 mg利福喷汀2个月;另一个新的治疗方案为每天服用乙胺丁醇片

NEJM:大剂量利福喷汀配合莫西沙星有效治疗肺结核

背景:相比于目前的6个月每日给药的方案来讲肺结核的治疗方案要简短一些。 方法: 我们随机分配新诊断的,痰检阳性,非肺结核的患者到三种方案之一:其中对照组包括2个月乙胺丁醇、异烟肼、利福平、吡嗪酰胺每日给药以及随后4个月每日给药异烟肼和利福平;4个月的方案是将对照组中异烟肼的给药方案替换成每天服用莫西沙星为期2个月随之是莫西沙星和900毫克的利福喷汀联合使用每周2次为期2个月的方案;6个月的方案是